Skip To Main Content
Rosanna C Barnard on Muck Rack

Rosanna C Barnard

As seen in: Nature, Science Magazine, The Lancet, HealthEconomics.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rosanna C

Contact Rosanna C, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The race to develop combination vaccines – and the importance of indirect effects - HealthEconomics.com

|
By Richard J. Pitman, Rosanna C Barnard, Hayleigh Culliton
| HealthEconomics.com
By: Richard Pitman, PhD & Rosanna Barnard, PhD from ICON A development race is currently underway in the field of combination vaccines, with a number of influential pharmaceutical and biotech companies pursuing combination vaccines targeting influenza and COVID-191.
Open in Who Shared Issue with article?

Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era - Nature Communications

|
By Rosanna C Barnard, Nicholas G Davies, W. John Edmunds
| Nature Verified
Abstract England has experienced a heavy burden of COVID-19, with multiple waves of SARS-CoV-2 transmission since early 2020 and high infection levels following the emergence and spread of Omicron variants since late 2021. In response to rising Omicron cases, booster vaccinations were accelerated and offered to all adults in England.
Open in Who Shared View Duplicates (2) Issue with article?

Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis

|
By Yang Liu, Carl A.B. Pearson, Frank G. Sandmann, Rosanna C Barnard
| The Lancet Verified
Summary Background In settings where the COVID-19 vaccine supply is constrained, extending the intervals between the first and second doses of the COVID-19 vaccine may allow more people receive their first doses earlier. Our aim is to estimate the health impact of COVID-19 vaccination alongside benefit-risk assessment of different dosing intervals in 13 middle-income countries (MICs) of Europe.
Open in Who Shared Issue with article?
See all 11 articles